We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




First-Ever Blood Test Detects Parkinson’s Disease

By LabMedica International staff writers
Posted on 24 Jun 2022

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. More...

However, the disease starts up to 20 years before it becomes noticeable as a result of these symptoms. To date, there have been neither blood parameters nor imaging examinations to produce a definite diagnosis, let alone early recognition. Scientists around the world are looking for reliable clinically applicable biomarkers for this chronic progressive brain disease. Now, researchers have developed a method that reliably detects protein changes in blood that are typical of Parkinson's disease.

A research team at the Faculty of Medicine at Kiel University (‎Schleswig-Holstein‎, Germany) has developed a biochemical blood-based test for the diagnosis of Parkinson's disease. In a study, the test was able to distinguish the 30 Parkinson’s patients from the 50 control individuals with a very high degree of sensitivity. However, it is still no known whether early stages of the diseases can also be detected and whether the test will work for diseases that are similar to Parkinson’s.

The new method is based on three steps. The first step was to isolate the vesicles of nerve cells in the blood sample. Vesicles are small blisters that are pinched off cells and contain the protein of the original cell. The second step was to look specifically for the protein that causes the disease in these isolated nerve cell vesicles. This is a changed form of α-synuclein. This pathogenic form of α-synuclein can be detected through structure-specific antibodies. The third and most significant step of the detection method involves reproducing these misfolded α-synuclein forms of Parkinson’s patients from vesicles taken from patients’ blood.

“We developed a biochemical blood-based test for the diagnosis of Parkinson's disease. With our procedure, we were able to distinguish the 30 Parkinson’s patients from the 50 control individuals with a very high degree of sensitivity,” said Dr. Annika Kluge from the Faculty of Medicine at Kiel University. “The results are really sensational. They form the basis on which a blood test for diagnosing Parkinson's disease can be developed.”

Related Links:
Kiel University 


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.